Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AZD0240

Cell therapy (TCR-T) · Kills target cells, directed at KRAS G12D · developed by ASTRAZENECA

Phase 1 Most advanced trial
AZN Developer
1 Registered trials

What is AZD0240?

AZD0240 is a T-cell receptor (TCR) engineered T-cell therapy targeting KRAS G12D mutations in patients with HLA-A*11:01 or HLA-A*11:02. It is being studied in non-small cell lung cancer, colorectal cancer, pancreatic cancer, and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (TCR-T)
Targets
KRAS G12D (antigen), HLA-A*11:01 (biomarker), HLA-A*11:02 (biomarker)
Mechanism
Kills target cells, directed at KRAS G12D
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06218914 Phase 1 Non-small Cell Lung Cancer Recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CarcinomaEndometrial CancerKRAS G12DNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaSolid Tumor, Adult

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD0240

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.